2022
PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer
Rozenblit M, Blenman K, Harigopal M, Reisenbichler E, Singh K, Qing T, Ibrahim E, Ramkissoon S, Asmelash S, Lin HK, Roberts M, Ross J, Huang RSP, Pusztai L. PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer. Breast Cancer Research And Treatment 2022, 196: 221-227. PMID: 36028784, DOI: 10.1007/s10549-022-06712-2.Peer-Reviewed Original ResearchConceptsPD-L1 positivityPD-L1 protein expressionPD-L1 expressionGrade 3 cancersPD-L1TIL scoreTumor gradeMultivariate analysisHigher PD-L1 positivityTumor-infiltrating lymphocyte countsConclusionPD-L1 expressionProtein expressionPD-L1 immunohistochemistryChi-square testResultsPD-L1T1 cancersLymphocyte countT3 tumorsIndependent predictorsTumor sizeLarge tumorsPositivity rateCell positivityBreast cancerGrade 2
2019
Interobserver variability in breast carcinoma grading results in prognostic stage differences
Rabe K, Snir OL, Bossuyt V, Harigopal M, Celli R, Reisenbichler ES. Interobserver variability in breast carcinoma grading results in prognostic stage differences. Human Pathology 2019, 94: 51-57. PMID: 31655171, DOI: 10.1016/j.humpath.2019.09.006.Peer-Reviewed Original ResearchConceptsPathologic prognostic stagePrognostic stageStage II carcinomaInterobserver variabilityIntra-observer variabilityGood intra-observer variabilityStage IABreast pathologistsConsecutive casesTumor gradeBreast carcinomaTumor gradingDiscordant gradesAJCC cancerDiscordant casesCarcinoma gradeInterobserver agreementGrading criteriaPathologistsCarcinomaComplete concordanceGradeOverall gradeGrading results